PrimeC can significantly slow ALS progression: PARADIGM trial
An analysis in 62 ALS patients who followed the Phase 2b study's rules (protocol) found a 37.4% ALSFRS-R difference with PrimeC vs. placebo.| ALS News Today
In adults with amyotrophic lateral sclerosis (ALS) who have slower disease progression, the stem cell therapy Neuronata-R (lenzumestrocel) — conditionally approved in South Korea for treating ALS — was found to […] The post In trial, Neuronata-R benefits ALS patients with slower progression appeared first on ALS News Today.| ALS News Today – The Web's Daily Resource for ALS News
An analysis in 62 ALS patients who followed the Phase 2b study's rules (protocol) found a 37.4% ALSFRS-R difference with PrimeC vs. placebo.| ALS News Today
Starting treatment with PrimeC six months sooner was associated with slower disease progression and a survival benefit for ALS patients.| ALS News Today
